Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q1 FY2027 Earnings Presentation
30 slides from Dr. Lal Pathlabs's earnings presentation, Jul 24, 2026
Slide 1: Exchange filing cover letter
July 24, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earnings Pr
Slide 2: Results Presentation Q1 FY2027
Results Presentation Q1 FY2027
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentati
Slide 4: Table of Contents
Table of Contents DLPL - At a Glance 4 Q1 FY27 Performance Overview 5 Financials 6 Key Performance Highlights 7 Management Commentary 9 Shareholding 14 Corporate Overview 16 Contact Us 28 DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operati
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 7,700+ 75+ years of India’s 141 Mn 53 NABL & experience Leading & patients 2 CAP in the field Trusted serviced in accredited of Diagnostics last 5 years Labs Patient Service Centers(PSC’s) diagnostics Company 4,800+ Pathology, Radiology tests & Panels; Comprehensive Te
Slide 6: Q1 FY27 Performance Overview
Q1 FY27 Performance Overview Q1 FY27 Q1 FY26 Gr % Revenue (Rs. Cr.) 798 670 19.1% EBITDA (Rs. Cr.) 247 192 28.7% PAT (Rs. Cr.) 170 134 27.2% Patients(Mn) 8.2 7.6 8.2% Samples(Mn) 25.9 23.4 10.7% SwasthFitTM Contribution 27% 27% - 5
Slide 7: Financials
Financials Reported Results (Rs. Cr.) Q1 FY27 Q1 FY26 Gr % FY26 Revenue 798 670 19.1% 2,763 Material consumed 152 129 535 Employee benefit Expenses 133 124 533 Fees to collection centres 116 96 402 Other Expenses 150 129 540 EBITDA 247 192 28.7% 752 Margins 31.0% 28.7% 27.2% Other Income 32 28 101 D
Slide 8: Key Performance Highlights- Q1 FY27
Key Performance Highlights- Q1 FY 27 Strong Revenue Growth Trajectory ➢ Highest quarterly Revenue growth in last 4 years ➢ Volume led Revenue growth driving strong performance for the quarter : • 10.7% YoY sample volume growth • 8.2% patient volume growth Key Pillars for growth • Scientific Leadersh
Slide 9: Operating highlights
Operating highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +35 +2,625 +2,997 298 312 7,727 13,935 277 280 6,607 11,619 12,365 5,762 10,938 5,102 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 No. of Patients (Mn) No. of Samples (Mn) +3.4 +22.2 85.6 94.5 28.8 30.3 78.2 26.
Slide 10: Management Commentary
Management Commentary (Hony.) Brig. Dr. Arvind Lal, Mr. Shankha Banerjee, Mr. Ved Goel, Padma Shri Chief Executive Officer Group CFO & Executive Chairman CEO – International Business Commenting on the performance, (Hony) Brig Dr Commenting on the performance, Mr. Shankha Commenting on the performanc
Slide 11: Robust financial performance
Robust financial performance (INR Cr.) (INR Cr.) (INR Cr.) Revenue Cash and Cash Equivalents EBITDA, PAT and ROCE 2,763 1,693 2,461 1,526 EBITDA PAT 2,227 2,017 1,229 783# 696 877 609 490 492 532# 601 798 362 241 247 170 FY23 FY24 FY25 FY26 Q1 FY27 FY23 FY24 FY25 FY26 Q1 FY27 FY23 FY24 FY25 FY26 Q1
Slide 12: Expanding Revenue Footprint Across Emerging Markets
Expanding Revenue Footprint Across Emerging Markets Revenue Tier 3+ CAGR 16.7% Geography wise Revenue Others, 2% 39% 37% South India, 6% 34% 35% 2,763 West India, 14% Delhi & NCR, 31% 2,461 2,227 2,017 Revenue by 1,090 Geography 789 917 FY26 685 East India, 15% FY23 FY24 FY25 FY26 Revenue Tier 3+ (I
Slide 13: Medillumina: First International Medical Conference by DLPL
Medllumina: First International Medical Conference by DLPL Conference Platform for Advancing Collaboration for Precision Clinicians, Global Podcast Series Diagnostics Thought Leaders & Pathologists Case Study Integrating Clinician AI and Engagement & Next-Gen Advocacy Digital Engagement Technology N
Slide 14: Research & Academic collaborations
Research & Academic collaborations Academia Collaborations In House Sustainability Partnerships • Fundamental Research • Novel Solutions • Educational Initiatives • Improve Core Processes • DOCTORAL & Multi • Clinical Trials • 49 ethics-approved • Contribute to ESG Omics Projects projects Initiative
Slide 15: Shareholding as of 30th June 2026
Shareholding as of 30th June 2026 17.63% FPI’s & NRI’s 53.19% Promoter and Promoter Group 10.10% Others 19.08% Mutual Fund* Promoter and Promoter Group Mutual Funds* Others FPI's & NRI's 14 *Mutual Funds includes Alternate Investment Funds as well
Slide 16: Key Awards & Recognition
Key Awards & Recognition Outstanding Contribution Rotary India National CSR Award in Healthcare from Rotary India National CSR Best CFO Healthcare India 2030 Leadership The CFO of the year 2026 Awards-National Level Foundation for Quality Awards-North Regional 2026 Conclave 2026 (India) in 2025 Leve
Slide 17: Corporate Overview
Corporate Overview NATIONAL KOLKATA BENGALURU MUMBAI REFERENCE LAB REFERENCE LAB REFERENCE LAB REFERENCE LAB 16
Slide 18: Indian Healthcare Services is a large and growing opportunity
Indian Healthcare Services is a large and growing opportunity ~1.51 bn 5% USD 1.5 trillion ~39% ~INR 1 trillion INR 42 billion India’s expected India’s projected spend Expected India’s Out of pocket expenses Allocated to the Allocated for Pradhan population on healthcare (as % of healthcare industry
Slide 19: Drivers of India diagnostic services market
Drivers of India diagnostic services market Lifestyle Diseases Longer Lifespans Preventive Checkups Growth Higher GDP per Drivers capita Evidence based Govt. Spend on treatment Primary Healthcare 18
Slide 20: Diagnostic Services industry continues to remain highly fragmented
Diagnostic Services industry continues to remain highly fragmented Highly Fragmented Industry Standalone Regional Centres Chains 42-46% 55% 16-20% Diagnostic Chains Multi- 36-40% Regional Hospital Based Labs 45% 19 Source: Industry Data
Slide 21: Our Evolution
Our Evolution 1949-2005 2005-2015 2015-2020 2020-2025 2025 onwards Foundation Building capabilities Higher contribution Pan India Player – Precision for scale up in from Rest of India, Acquired Suburban, Diagnostics, • 1949: Founded by Dr. geographies outside Commissioned state Building South Levera
Slide 22: Most trusted healthcare brand in Diagnostic Services
Most trusted healthcare brand in Diagnostic Services 30.3M+ 13,900+ 4,800+ 53 2 Patients Serviced Pick-up Points Pathology & Radiology NBAL Accredited CAP Accredited in FY26 tests; Comprehensive Labs Labs Test menu Coverage in 24x7 access Centrally Accreditations metros, Wide reach including adminis
Slide 23: Scaling Rural Healthcare
Scaling Rural Healthcare GraminFit is creating a scalable rural preventive healthcare program, unlocking a large underserved diagnostics market. Expanded Reach -7 States Attract Educate Convert UP, Bihar, MP, Raj, Jharkhand Orissa, West Bengal Patients served more than 100K in Q1 FY27 Village Mandi
Slide 24: DLPL Strategy for future growth
DLPL Strategy for future growth Scientific AI Technology New Revenue Leadership Models Patient Merger & Experience Acquisitions Operational International Excellence Business People 23
Slide 25: Unleashing Digital Transformation
Unleashing Digital Transformation Driving efficiency & elevating customer experience Operations Consumers Medical • GenAl & curated healthcare • Unified Communication Engine • Smart Culture Reporting: models managing interactions • WhatsApp as forefront Advancing Quality through • 90% queries handle
Slide 26: Cyber Security Capability
Cyber Security Capability • SASE - Secure Access Service Edge, Extended • Digital Risk Management Platform • EDR - Endpoint Detection & Response Threat Detection • Proactive detection and mitigation of Intelligence & Response • Cloud Native SIEM/SOAR for AI-driven security vulnerabilities of publicl
Slide 27: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 98.1% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.2% for Satellite Labs CAP accreditation 2 labs, NABL accreditation 53 labs 100+ Quality Real time NABL Tech Assure i
Slide 28: Key ESG Initiatives
Key ESG Initiatives Use of biodegradable Installed R32 refrigerant bags for sample operated Inverter AC for collection Conserving ozone layer Saved 2515 Metric ton All labs are equipped of CO2 emissions by with Effluent Treatment using Solar power Plant for wastewater treatment Use of Electric 56,71
Slide 29: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests
Slide 30: Thank you
3D Lat Pathlabe